Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs GSK 3532795 (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 26 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Jun 2014 Planned number of patients changed from 32 to 28 as reported by ClinicalTrials.gov record.
- 26 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.